白佳坤;马晓阳;李霄鹤;周红刚;
BAI Jiakun;MA Xiaoyang;LI Xiaohe;ZHOU Honggang;College of Pharmacy,Nankai University;Tianjin International Joint Academy of Biomedicine;

• 1:南开大学药学院
• 2:天津国际生物医药联合研究院

摘要(Abstract)：

目的探索SARS-CoV-2的治疗靶点,治疗药物和疫苗研发的近况,为其后期的研究提供思路。方法通过检索国内外的专业数据库,对SARS-CoV-2的最新文献进行解读,获取相关数据。结果目前研究出2个抗病毒药物靶点,一个抗体和疫苗的靶点及一个开发检测试剂的靶点,可能的有效药物和疫苗也已经开始临床研究。结论目前SARS-CoV-2的针对性靶点已清楚,候选药物和疫苗的疗效尚待确认。
OBJECTIVE To explore the targets of treatment,the therapeutic drugs and the recent development of vaccines of SARS-Co V-2,and to provide some ideas for its later research. METHODS The latest SARS-Co V-2 literatures were interpretedand relevant data were obtained by searching professional databases at home and abroad. RESULTS Two antiviral drug targets,one antibody and vaccine target,and one target for developing detection reagents have been developed in recent. The possible effective drugs and vaccines have started clinical research. CONCLUSION The targets of SARS-Co V-2 are clear now. And the clinical efficacy of candidate medicines and vaccines have yet to be confirmed.

关键词(KeyWords)： 新型冠状病毒;靶点;治疗药物;疫苗
SARS-Co V-2;targets;therapeutic drugs;vaccines

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 白佳坤;马晓阳;李霄鹤;周红刚;
BAI Jiakun;MA Xiaoyang;LI Xiaohe;ZHOU Honggang;College of Pharmacy,Nankai University;Tianjin International Joint Academy of Biomedicine;

Email:

DOI:

参考文献(References)：

• [1]Mourya D T,Sapkal G,Yadav P D,et al.Biorisk assessment for infrastructure&biosafety requirements for the laboratories providing coronavirus SARS-Co V-2/(COVID-19) diagnosis[J].The Indian Journal of Medical Research,2020,151(3):172-176．
• [2]Daniel K W C,Yang P,Samuel M S C,et al.Molecular diagnosis of a novel coronavirus(2019-n Co V) causing an outbreak of pneumonia[J].Clinical Chemistry,2020,66(4):549-555．
• [3]Li X,Wang W,Zhao X,et al.Transmission dynamics and evolutionary history of 2019-n Co V[J].Journal of Medical Virology,2020,92(5):501-511．
• [4]周娟，李丹，龙云铸．新型冠状病毒(2019-n Co V)相关研究进展[J]．中国感染控制杂志，2020,19(3):288-292．
• [5]Park S E.Epidemiology,virology,and clinical features of severe acute respiratory syndrome-coronavirus-2(SARS-Co V-2;Coronavirus Disease-19)[J].Clinical and experimental pediatrics,2020,63(4):119-124．
• [6]Dong S J,Sun J C,Mao Z,et al.A guideline for homology modeling of the proteins from newly discovered betacoronavirus,2019 novel coronavirus(2019-n Co V)[J].Journal of Medical Virology,2020.Doi:10.1002/jmv.25768．
• [7]Qamar M T U,Alqahtani S M,Alamri M A,et al.Structural Basis of SARS-Co V-2 3CLpro and Anti-COVID-19 Drug Discovery from Medicinal Plants[J].Journal of Pharmaceutical Analysis,2020,10(4):313-319．
• [8]苏彦雷，段绪红，许文成，等．以RNA依赖的RNA聚合酶为靶点的抗新型冠状病毒抑制剂筛选[J/OL]．中华中医药学刊，2020,38(5):7-13,259-260．
• [9]Li F.Structure,Function,and Evolution of Coronavirus Spike Proteins[J].Annual Review of Virology,2016,3(1):237-261．
• [10]Li F.Receptor recognition and cross-species infections of SARScoronavir us[J].Antiviral Res,2013,100(1):246-254．
• [11]Rabaan A A,Al-Ahmed S H,Haque S,et al.SARS-Co V-2,SARS-Co V,and MER S-COV:A comparative overview[J].Le Infezioni in Medicina,2020,28(2):174-184．
• [12]Song W,Gui M,Wang X,et al.Cryo-EM structure of the SARScoronav irus spike glycoprotein in complex with its host cell receptor ACE2.[J].PLOS Pathogens,2018,14(8):e1007236．
• [13]李思远，孙希．新型冠状病毒肺炎(COVID-19)防治药物研究进展[J]．热带医学杂志，2020,20(3):286-288．
• [14]生物通．克力芝和阿比朵尔治新冠收效甚微，或反而拖慢转阴[J].http:∥www.ebio trade.com/newsf/2020-3/2020325120909307.htm．
• [15]Wang M,Cao R,Zhang L,et al.Remdesivir and chloroquine effecti vely inhibit the recently emerged novel coronavirus(2019-n Co V) in vitro[J].Cell Res,2020,30(3):269-271．
• [16]Warren T K,Jordan R,Lo Michael K,et al.Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys[J].Nature,2016,531(7594):381-385．
• [17]Holshue M L,Debolt C,Lindquist S,et al.First case of 2019 n ove l coronavirus in the United States[J].The New England Journal of Medicine,2020,382(10):929-936．
• [18]Sanville B,Corbett R,Pidcock W,et al.A Community Transmitted Case of Severe Acute Respiratory Distress Syndrome due to SARSCo V2 in the United States[J].Clinical Infectious Diseases,2020.Doi:10.1093/cid/ciaa347．
• [19]苗青，丛晓东，王冰，等．新型冠状病毒肺炎的中医认识与思考[J]．中医杂志，2020,61(4):286-288．
• [20]邹璐，喻晓，吴雨沁，等．中医药防治重症新型冠状病毒肺炎的分析和思考[J]．上海中医药大学学报，2020,34(2):11-16．
• [21]北京商报．国家卫健委:筛选出金花清感颗粒、莲花清瘟胶囊、清肺排毒汤等有明显疗效的“三药三方”[N/OL].http:∥sa.sogou.com/sgsearch/sgs_tc_news.php?r eq=g N-Wj Mh9kjp Et YgjRe Td UXb Sg AHZQNPlk IMkRt Cqn_LHhsw EVA-g Os Cn Je VFCAMGt&user_type=1．
• [22]中国红十字基金会．新冠肺炎恢复期血浆:有望成为挽救重症新冠肺炎患者生命的有力武器[N/OL].https:∥new.crcf.org.cn/article/19780．
• [23]中国生物技术股份有限公司．重磅消息!中国生物治疗性新冠特免血浆制品投入临床[EB/OL].[2020-02-28].https:∥www.cnbg.com.cn/．
• [24]Tai W,He L,Zhang X,et al.Characterization of the receptor-binding do mai n(RBD) of 2019 novel coronavirus:implication for development of RBD p rotein as a viral attachment inhibitor and vaccine[J].Cellular&Molecular Immunology,2020.Doi:10.1038/S41423-020-0400-4．
• [25]Tian X L,Li C,Huang A L,et al.Potent binding of 2019 novel c oronavirus spike protein by a SARS coronavirus-specific human monoclon al antibody[J].Emerging Microbes&Infections,2020,9(1):382-385．
• [26]Wrapp D,Wang N,Corbett K S,et al.Cryo-EM structure of the2019-n Co V spike in the prefusion conformation[J].Science,2020,367(6483):1260-1263.